Tan L.,Institute of Medical Laboratory Reagents in Chongqing |
Xu L.,Institute of Medical Laboratory Reagents in Chongqing |
Tian S.,Institute of Medical Laboratory Reagents in Chongqing |
Yang Z.,Institute of Medical Laboratory Reagents in Chongqing |
And 4 more authors.
Journal of Pure and Applied Microbiology | Year: 2013
This report aimed to analyze screening on mutations of resistance to drug in hepatitis B virus (HBV) during patient treatment using lamivudine and adefovir dipivoxil. Methods: A 40-year-old Chinese man presented to Chongqing Cancer Hospital, with hepatitis B surface antigen-positive and HBeAg-positive chronic HBV and was sequentially treated with LAM 100mg/d for 16 weeks, and LAM 50 mg/d + ADV 10mg/d for 16 weeks. The primers P1(5′- AAGGGTATCTTGCCCGTTTGTCGTA-3′) P2(5′-AAGCAGGATAGCCACAGA-3′) and P3(5′-AAGGCACTTGTATTCCCATCCGAG-3′) P4 (5′- AAGGTCTATTTACAGGGGA-3′) was used to analyzed the RT region of the polymerase gene from the serum of the patient at weeks 0, 18, 22, 60 and 70. Results: The mutation M204V and T213T were detected prior to treatment, At week 18 during LAM treatment, the mutation LMV rtH69T (YMDDlocus) was identified, At week 22 during LAM treatment, the mutations LMV rtT184T(YMDDlocus) and LMV rtM204I (YMDDlocus). At week 60 during LAM + ADV treatment, the mutations ADV T213S0ADV T222A and ADV K212T were detected, at week 70 during LAM + ADV treatment, the mutations ADV S196L and ADV S242H were detected, The mutations ADV S196L and ADV S242H were detected firstly. Conclusions: The report detected HBV mutations that escaped the antiviral pressure of LAM and LAM + ADV in the patient and provided insight into the molecular mechanism of the drug resistance for HBV virus.